Platelet function testing and prediction of procedural bleeding risk

Thrombosis and Haemostasis

Volumn 109, Issue 5, 2013, Pages 817-824

  Grove, Erik L ^a   Hossain, Rashed ^b   Storey, Robert F ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Adp receptors; Antiplatelet agents; Antiplatelet drugs; Clinical trials; Haemostasis; Platelet pharmacology

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; APROTININ; CLOPIDOGREL; CYCLOOXYGENASE 1; CYTOCHROME P450 2C19; FIBRINOGEN; FIBRINOGEN RECEPTOR; GLYCOPROTEIN P INHIBITOR; GLYCOPROTEIN VI; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PRASUGREL; PROSTACYCLIN; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 4; PURINERGIC P2Y12 RECEPTOR; THROMBOXANE A2; THROMBOXANE B2; TICAGRELOR; TIROFIBAN; TRANEXAMIC ACID; UNINDEXED DRUG; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ALLELE; ARTICLE; BLEEDING; CORONARY ARTERY BYPASS GRAFT; FLOW CYTOMETRY; HEMOSTASIS; HUMAN; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK; SYSTEMATIC REVIEW (TOPIC); THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOSIS;

ANIMALS; BLOOD PLATELETS; CORONARY ARTERY BYPASS; HEMORRHAGE; HEMOSTASIS; HUMANS; PERCUTANEOUS CORONARY INTERVENTION; PHARMACOGENETICS; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; POSTOPERATIVE HEMORRHAGE; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS;

EID: 84877013453     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-11-0806     Document Type: Article

References (64)

1. Nurden A, Nurden P. Advances in our understanding of the molecular basis of disorders of platelet function. J Thromb Haemost 2011; 9: 76-91
2. Nurden A. Glanzmann thrombasthenia. Orphanet J Rare Dis 2006; 1: 10
3. Patrono C, Ciabattoni G, Patrignani P, et al. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 1985; 72: 1177-1184
4. Schwartz KA, Schwartz DE, Ghosheh K, et al. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol 2005; 95: 973-975
5. Ajjan RA, Standeven KF, Khanbhai M, et al. Effects of Aspirin on Clot Structure and Fibrinolysis Using a Novel In Vitro Cellular System. Arterioscl Thromb Vasc Biol 2009; 29: 712-717
6. Patrono C, Andreotti F, Arnesen H, et al. Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur Heart J 2011; 32: 2922-2932
7. Sun JCJ, Whitlock R, Cheng J, et al. The effect of pre-operative aspirin on bleeding, transfusion, myocardial infarction, and mortality in coronary artery bypass surgery: a systematic review of randomized and observational studies. Eur Heart J 2008; 29: 1057-1071
8. Storey RF. Biology and pharmacology of the platelet P2Y12 receptor. Curr Pharm Des 2006; 12: 1255-1259
9. Storey RF, Sanderson HM, White AE, et al. The central role of the P2T receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br J Haematol 2000; 110: 925-934
10. Cattaneo M. Congenital and drug-induced defects of the platelet P2Y12 receptor for adenosine diphosphate. Thromb Haemost 2011; 105 (Suppl 1): S67-74
11. Andre P, Delaney SM, LaRocca T, et al. P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries. J Clin Invest 2003; 112: 398-406
12. De Caterina R, Sicari R, Bernini W, et al. Benefit/risk profile of combined antiplatelet therapy with ticlopidine and aspirin. Thromb Haemost 1991; 65: 504-510
13. Judge HM, Buckland R, Sugidachi A, et al. Relationship between degree of P2Y12 receptor blockade and inhibition of P2Y12-mediated platelet function. Thromb Haemost 2010; 103: 1210-1217
14. Wiviott S, Braunwald E, McCabe C, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015
15. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med 2009; 361: 1045-1057
16. Yusuf S, Zhao F, Mehta S, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502
17. Serebruany V, Rao SV, Silva MA, et al. Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications. Eur Heart J 2010; 31: 227-235
18. Michelson AD, Frelinger AL, Braunwald E, et al. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J 2009; 30: 1753-1763
19. Grove EL, Storey RF, Würtz M. Platelet function testing in atherothrombotic disease. Curr Pharm Des 2012; 18: 5379-5391
20. Grove EL, Hvas AM, Johnsen HL, et al. A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease. Thromb Haemost 2010; 103: 1245-1253
21. Armstrong PCJ, Truss NJ, Ali FY, et al. Aspirin and the in vitro linear relationship between thromboxane A2-mediated platelet aggregation and platelet production of thromboxane A2. J Thromb Haemost 2008; 6: 1933-1943
22. Perneby C, Wallén NH, Rooney C, et al. Dose- and time-dependent antiplatelet effects of aspirin. Thromb Haemost 2006; 95: 652-658
23. Henry P, Vermillet A, Boval B, et al. 24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease. Thromb Haemost 2011; 105: 336-344
24. Deja MA, Kargul T, Domaradzki W, et al. Effects of preoperative aspirin in coronary artery bypass grafting: A double-blind, placebo-controlled, randomized trial. J Thoracic Cardiovasc Surg 2012; 144: 204-209.e3
25. Fox KAA, Mehta SR, Peters R, et al. Benefits and Risks of the Combination of Clopidogrel and Aspirin in Patients Undergoing Surgical Revascularization for Non-ST-Elevation Acute Coronary Syndrome. The Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 2004; 110: 1202-8
26. Gurbel PA, Bliden KP, Butler K, et al. Randomized Double-Blind Assessment of the ONSET and OFFSet of the Antiplatelet Effects of Ticagrelor versus Clopidogrel in Patients with Stable Coronary Artery Disease: The ONSET/OFFSET Study. Circulation 2009; 120: 2577-2585
27. Au AG, Majumdar SR, McAlister FA. Preoperative Thienopyridine Use and Outcomes after Surgery: A Systematic Review. Am J Med 2012; 125: 87-99.e1
28. Hamm CW, Bassand J-P, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2011; 32: 2999-3054
29. Storey RF, Bliden KP, Ecob R, et al. Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared to clopidogrel in patients with high antiplatelet responses. J Thromb Haemost 2011; 9: 1730-1737
30. Price MJ, Walder JS, Baker BA, et al. Recovery of Platelet Function After Discontinuation of Prasugrel or Clopidogrel Maintenance Dosing in Aspirin- Treated Patients With Stable Coronary Disease: The Recovery Trial. J Am Coll Cardiol 2012; 59: 2338-2343
31. Held C, Åsenblad N, Bassand JP, et al. Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery: Results From the PLATO (Platelet Inhibition and Patient Outcomes) Trial. J Am Coll Cardiol 2011; 57: 672-684
32. Varenhorst C, Alstrom U, Scirica BM, et al. Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery. J Am Coll Cardiol 2012; 60: 1623-1630
33. Tantry US, Gurbel PA. Assessment of oral antithrombotic therapy by platelet function testing. Nat Rev Cardiol 2011; 8: 572-579
34. Chen L, Bracey AW, Radovancevic R, et al. Clopidogrel and bleeding in patients undergoing elective coronary artery bypass grafting. J Thorac Cardiovasc Surg 2004; 128: 425-431
35. Rahe-Meyer N, Winterhalter M, Boden A, et al. Platelet concentrates transfusion in cardiac surgery and platelet function assessment by multiple electrode aggregometry. Acta Anaesthesiol Scand 2009; 53: 168-175
36. Poston R, Gu J, Manchio J, et al. Platelet function tests predict bleeding and thrombotic events after off-pump coronary bypass grafting. Eur J Cardio Thoracic Surg 2005; 27: 584-591
37. Kwak Y-L, Kim J-C, Choi Y-S, et al. Clopidogrel Responsiveness Regardless of the Discontinuation Date Predicts Increased Blood Loss and Transfusion Requirement After Off-Pump Coronary Artery Bypass Graft Surgery. J Am Coll Cardiol 2010; 56: 1994-2002
38. Ranucci M, Baryshnikova E, Soro G, Ballotta A, De Benedetti D, Conti D. Multiple Electrode Whole-Blood Aggregometry and Bleeding in Cardiac Surgery Patients Receiving Thienopyridines. Ann Thoracic Surg 2011; 91: 123-129
39. Mahla E, Suarez TA, Bliden KP, et al. Platelet Function Measurement-Based Strategy to Reduce Bleeding and Waiting Time in Clopidogrel-Treated Patients Undergoing Coronary Artery Bypass Graft Surgery. Circulation Cardiovasc Interv 2012; 5: 261-269
40. van der Linden J, Lindvall G, Sartipy U. Aprotinin Decreases Postoperative Bleeding and Number of Transfusions in Patients on Clopidogrel Undergoing Coronary Artery Bypass Graft Surgery: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial. Circulation 2005; 112: I-276-280
41. Akowuah E, Shrivastava V, Jamnadas B, et al. A prospective randomized comparison of two strategies for the management of patients with acute coronary syndrome on clopidogrel and aspirin therapy requiring urgent coronary artery bypass graft surgery. Ann Thoracic Surg 2005; 80: 149-152
42. Olenchock SA, Lee PHU, Yehoshua T, et al. Impact of Aprotinin on Adverse Clinical Outcomes and Mortality up to 12 Years in a Registry of 3,337 Patients. Ann Thoracic Surg 2008; 86: 560-567
43. Ferraris VA, Saha SP, Oestreich JH, et al. 2012 Update to The Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations. Ann Thoracic Surg 2012; 94: 1761-1781
44. Mehta SR, Yusuf S, Peters RJG, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-533
45. Becker RC, Bassand JP, Budaj A, et al. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 2011; 32: 2933-2944
46. Mehta SR, Tanguay JF, Eikelboom JW, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT- OASIS 7): a randomised factorial trial. Lancet 2010; 376: 1233-1243
47. Jernberg T, Payne C, Winters K, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006; 27: 1166-1173
48. Jakubowski J, Winters K, Naganuma H, et al. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc Drug Rev 2007; 25: 357-374
49. Storey RF, Angiolillo D, Patil S, et al. Inhibitory Effects of Ticagrelor Compared to Clopidogrel on Platelet Function in Patients with Acute Coronary Syndromes: the PLATO PLATELET Substudy. J Am Coll Cardiol 2010; 56: 1456-1462
50. Price MJ, Berger PB, Teirstein PS, et al. Standard- vs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention. J Am Med Assoc 2011; 305: 1097-1105
51. Sibbing D, Schulz S, Braun S, et al. Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J Thromb Haemost 2010; 8: 250-256
52. Sibbing D, Koch W, Gebhard D, et al. Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel- Treated Patients With Coronary Stent Placement. Circulation 2010; 121: 512-518
53. Sibbing D, Steinhubl SR, Schulz S, et al. Platelet Aggregation and Its Association With Stent Thrombosis and Bleeding in Clopidogrel-Treated Patients: Initial Evidence of a Therapeutic Window. J Am Coll Cardiol 2010; 56: 317-318
54. Cuisset T, Cayla G, Frere C, et al. Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment? EuroIntervention 2009; 5: 325-329
55. Harmsze AM, van Werkum JW, Hackeng CM, et al. The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting. Pharmacogenet Genomics 2012; 22: 169-175
56. Mokhtar OA, Lemesle G, Armero S, et al. Relationship between platelet reactivity inhibition and non-CABG related major bleeding in patients undergoing percutaneous coronary intervention. Thromb Res 2010; 126: e147-e149
57. Patti G, Pasceri V, Vizzi V, et al. Usefulness of Platelet Response to Clopidogrel by Point-of-Care Testing to Predict Bleeding Outcomes in Patients Undergoing Percutaneous Coronary Intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study). Am J Cardiol 2011; 107: 995-1000
58. Cuisset T, Frere C, Quilici J, et al. Glycoprotein IIb/IIIa Inhibitors Improve Outcome After Coronary Stenting in Clopidogrel Nonresponders: A Prospective, Randomized Study. JACC 2008; 1: 649-653
59. Valgimigli M, Campo G, de Cesare N, et al. Intensifying Platelet Inhibition With Tirofiban in Poor Responders to Aspirin, Clopidogrel, or Both Agents Undergoing Elective Coronary Intervention: Results From the Double-Blind, Prospective, Randomized Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel Study. Circulation 2009; 119: 3215-3222
60. Kristensen SD, Würtz M, Grove EL, et al. Contemporary use of glycoprotein IIb/ IIIa inhibitors. Thromb Haemost 2012; 107: 215-224
61. Breet N, van Werkum J, Bouman H, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. J Am Med Assoc 2010; 303: 754-762
62. Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 2010; 376: 1320-1328
63. Cayla G, Cuisset T, Silvain J, et al. Prasugrel Monitoring and Bleeding in Real World Patients. Am J Cardiol 2013; 111: 38-44
64. Price MJ, Murray SS, Angiolillo DJ, et al. Influence of Genetic Polymorphisms on the Effect of High- and Standard-Dose Clopidogrel After Percutaneous Coronary Intervention: The GIFT (Genotype Information and Functional Testing) Study. J Am Coll Cardiol 2012; 59: 1928-1937.